JP2014506785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506785A5 JP2014506785A5 JP2013552568A JP2013552568A JP2014506785A5 JP 2014506785 A5 JP2014506785 A5 JP 2014506785A5 JP 2013552568 A JP2013552568 A JP 2013552568A JP 2013552568 A JP2013552568 A JP 2013552568A JP 2014506785 A5 JP2014506785 A5 JP 2014506785A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- mva
- vaccinia virus
- gene cassette
- recombinant vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700618 Vaccinia virus Species 0.000 claims description 77
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 108020001507 fusion proteins Proteins 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 208000037797 influenza A Diseases 0.000 claims description 21
- 102000011931 Nucleoproteins Human genes 0.000 claims description 10
- 108010061100 Nucleoproteins Proteins 0.000 claims description 10
- 241000712431 Influenza A virus Species 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 239000000185 hemagglutinin Substances 0.000 claims description 6
- 101710199771 Matrix protein 1 Proteins 0.000 claims description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 96
- 238000012217 deletion Methods 0.000 description 40
- 230000037430 deletion Effects 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 26
- 102000007999 Nuclear Proteins Human genes 0.000 description 23
- 108010089610 Nuclear Proteins Proteins 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 108091029795 Intergenic region Proteins 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 10
- 101150082969 SELP gene Proteins 0.000 description 9
- 101150036293 Selenop gene Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 102000006601 Thymidine Kinase Human genes 0.000 description 8
- 108020004440 Thymidine kinase Proteins 0.000 description 8
- -1 HA1 amino acids Chemical class 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 101150118742 NP gene Proteins 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101150039660 HA gene Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438024P | 2011-01-31 | 2011-01-31 | |
| US61/438,024 | 2011-01-31 | ||
| PCT/US2012/023085 WO2012106231A2 (en) | 2011-01-31 | 2012-01-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017126499A Division JP6461244B2 (ja) | 2011-01-31 | 2017-06-28 | インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506785A JP2014506785A (ja) | 2014-03-20 |
| JP2014506785A5 true JP2014506785A5 (enExample) | 2015-03-19 |
| JP6169494B2 JP6169494B2 (ja) | 2017-07-26 |
Family
ID=45561167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552568A Active JP6169494B2 (ja) | 2011-01-31 | 2012-01-30 | インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 |
| JP2017126499A Active JP6461244B2 (ja) | 2011-01-31 | 2017-06-28 | インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017126499A Active JP6461244B2 (ja) | 2011-01-31 | 2017-06-28 | インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9463237B2 (enExample) |
| EP (1) | EP2670430B1 (enExample) |
| JP (2) | JP6169494B2 (enExample) |
| CN (1) | CN103458922B (enExample) |
| AU (2) | AU2012212463B2 (enExample) |
| WO (1) | WO2012106231A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2670430B1 (en) * | 2011-01-31 | 2015-04-01 | Baxter International Inc | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
| US10434166B2 (en) * | 2013-03-15 | 2019-10-08 | University Of Maryland, College Park | Methods and compositions for in vivo immune stimulation and antigen production |
| US10286062B2 (en) | 2013-07-09 | 2019-05-14 | Texas Tech University System | Universal influenza vaccine |
| CA3003103A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| PL3402802T3 (pl) * | 2016-01-08 | 2023-06-05 | Geovax, Inc. | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
| US10370416B2 (en) * | 2016-03-01 | 2019-08-06 | Texas Tech University System | Dual purpose universal influenza vaccine confers protective immunity against anthrax |
| KR102731582B1 (ko) | 2016-06-03 | 2024-11-15 | 사노피 파스퇴르 인코포레이티드 | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| JP7382634B2 (ja) * | 2017-12-21 | 2023-11-17 | 株式会社グリーンバイオメッド | 交差免疫抗原ワクチン及びその調製方法 |
| CN109096376A (zh) * | 2018-09-20 | 2018-12-28 | 扬州大学 | 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法 |
| CN113004422B (zh) * | 2021-03-04 | 2023-01-20 | 辽宁成大生物股份有限公司 | 一种融合蛋白、含其的疫苗及其应用 |
| WO2023019274A1 (en) * | 2021-08-13 | 2023-02-16 | Purdue Research Foundation | Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| AT393277B (de) | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| MX2008009929A (es) * | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| EP1820511A1 (en) * | 2006-02-20 | 2007-08-22 | Prolmmune Limited | MHC binding peptides and their uses |
| CA2673994A1 (en) * | 2006-12-29 | 2008-07-24 | Institut Pasteur Of Shanghai | Lentivirus pseudotyped with influenza hemagglutinin and methods of use |
| EP2134361A4 (en) * | 2007-03-26 | 2010-09-22 | Univ Massachusetts Medical | Compositions and methods for increasing immunogenicity of glycoprotein vaccines |
| US20110177122A1 (en) * | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| EP2413962A1 (en) * | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| CA2762044A1 (en) | 2009-05-18 | 2010-11-25 | Panacea Biotec Ltd | Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva) |
| EP2670430B1 (en) | 2011-01-31 | 2015-04-01 | Baxter International Inc | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
-
2012
- 2012-01-30 EP EP12702162.4A patent/EP2670430B1/en active Active
- 2012-01-30 AU AU2012212463A patent/AU2012212463B2/en active Active
- 2012-01-30 JP JP2013552568A patent/JP6169494B2/ja active Active
- 2012-01-30 WO PCT/US2012/023085 patent/WO2012106231A2/en not_active Ceased
- 2012-01-30 CN CN201280015880.9A patent/CN103458922B/zh active Active
- 2012-01-30 US US13/982,524 patent/US9463237B2/en active Active
-
2016
- 2016-09-30 AU AU2016235002A patent/AU2016235002B2/en active Active
- 2016-10-07 US US15/289,106 patent/US10329583B2/en active Active
-
2017
- 2017-06-28 JP JP2017126499A patent/JP6461244B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506785A5 (enExample) | ||
| Watanabe et al. | Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes | |
| Gu et al. | Current situation of H9N2 subtype avian influenza in China | |
| Fan et al. | Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice | |
| Mair et al. | Receptor binding and pH stability—How influenza A virus hemagglutinin affects host-specific virus infection | |
| Cotter et al. | A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity | |
| Ping et al. | Development of high-yield influenza A virus vaccine viruses | |
| Paterson et al. | Emerging roles for the influenza A virus nuclear export protein (NEP) | |
| Steinhauer et al. | Genetics of influenza viruses | |
| CA3014435C (en) | Improved influenza b virus replication for vaccine development | |
| EP2493912B1 (en) | High titer recombinant influenza viruses with enhanced replication in vero cells | |
| JP2015119730A5 (enExample) | ||
| CN103458922B (zh) | 诱导对甲型流感病毒的异源亚型免疫反应的重组病毒载体和方法 | |
| Isakova-Sivak et al. | Influenza vaccine: Progress in a vaccine that elicits a broad immune response | |
| Cornax et al. | Newcastle disease virus fusion and haemagglutinin-neuraminidase proteins contribute to its macrophage host range | |
| Kim et al. | Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice | |
| Li et al. | Development and application of reverse genetic technology for the influenza virus | |
| Martin-Benito et al. | Influenza virus transcription and replication | |
| Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
| DeHaven et al. | The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins | |
| Song et al. | Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production | |
| Looi et al. | How far have we reached in development of effective influenza vaccine? | |
| CN104592367A (zh) | 流感病毒np蛋白突变体及其编码基因与应用 | |
| de Wit et al. | Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene | |
| RU2020125098A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита |